Literature DB >> 29242295

The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors.

Hanny Al-Samkari1, Ariela L Marshall2, Katayoon Goodarzi3, David J Kuter3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29242295      PMCID： PMC5865422          DOI： 10.3324/haematol.2017.180166

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

1.  Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.

Authors:  M Fanucchi; J Glaspy; J Crawford; J Garst; R Figlin; W Sheridan; D Menchaca; D Tomita; H Ozer; L Harker
Journal:  N Engl J Med       Date:  1997-02-06       Impact factor: 91.245

2.  Romiplostim for management of chemotherapy-induced thrombocytopenia.

Authors:  R Parameswaran; M Lunning; S Mantha; S Devlin; A Hamilton; G Schwartz; G Soff
Journal:  Support Care Cancer       Date:  2014-01-12       Impact factor: 3.603

Review 3.  The biology of thrombopoietin and thrombopoietin receptor agonists.

Authors:  David J Kuter
Journal:  Int J Hematol       Date:  2013-07-03       Impact factor: 2.490

4.  Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.

Authors:  S Vadhan-Raj; C F Verschraegen; C Bueso-Ramos; H E Broxmeyer; A P Kudelkà; R S Freedman; C L Edwards; D Gershenson; D Jones; M Ashby; J J Kavanagh
Journal:  Ann Intern Med       Date:  2000-03-07       Impact factor: 25.391

5.  Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.

Authors:  C H Moskowitz; P A Hamlin; J Gabrilove; J R Bertino; C S Portlock; D J Straus; A N Gencarelli; S D Nimer; A D Zelenetz
Journal:  Ann Oncol       Date:  2007-09-14       Impact factor: 32.976

6.  A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.

Authors:  I Tepler; L Elias; J W Smith; M Hussein; G Rosen; A Y Chang; J O Moore; M S Gordon; B Kuca; K J Beach; J W Loewy; M B Garnick; J A Kaye
Journal:  Blood       Date:  1996-05-01       Impact factor: 22.113

7.  Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices.

Authors:  Neelima Denduluri; Debra A Patt; Yunfei Wang; Menaka Bhor; Xiaoyan Li; Anne M Favret; Phuong Khanh Morrow; Richard L Barron; Lina Asmar; Shanmugapriya Saravanan; Yanli Li; Jacob Garcia; Gary H Lyman
Journal:  J Natl Compr Canc Netw       Date:  2015-11       Impact factor: 11.908
  7 in total
  9 in total

1.  Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.

Authors:  David J Kuter
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

2.  Romiplostim for chemotherapy-induced thrombocytopenia: Efficacy and safety of extended use.

Authors:  Cy R Wilkins; Jocelyn Ortiz; Leah J Gilbert; Shen Yin; Jodi V Mones; Rekha Parameswaran; Simon Mantha; Gerald A Soff
Journal:  Res Pract Thromb Haemost       Date:  2022-05-10

3.  Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia.

Authors:  Gerald A Soff; Isabelle Ray-Coquard; Luis J Marfil Rivera; Jon Fryzek; Megan Mullins; Lauren C Bylsma; Joseph K Park
Journal:  PLoS One       Date:  2022-06-09       Impact factor: 3.752

4.  The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies.

Authors:  Jaime L Shaw; Carrie M Nielson; Joseph K Park; Andrea Marongiu; Gerald A Soff
Journal:  Eur J Haematol       Date:  2021-02-16       Impact factor: 2.997

5.  A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.

Authors:  Hanny Al-Samkari; Aric D Parnes; Katayoon Goodarzi; James I Weitzman; Jean M Connors; David J Kuter
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

6.  The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia.

Authors:  Wenxian Wang; Xiaodong Gu; Lan Shao; Zhiyong Shi; Guangyuan Lou; Zhengbo Song; Yiping Zhang
Journal:  Contrast Media Mol Imaging       Date:  2022-07-14       Impact factor: 3.009

Review 7.  A Review of Romiplostim Mechanism of Action and Clinical Applicability.

Authors:  James B Bussel; Gerald Soff; Adriana Balduzzi; Nichola Cooper; Tatiana Lawrence; John W Semple
Journal:  Drug Des Devel Ther       Date:  2021-05-26       Impact factor: 4.162

Review 8.  Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease.

Authors:  Abraham Z Cheloff; Hanny Al-Samkari
Journal:  J Blood Med       Date:  2019-09-05

9.  Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.

Authors:  Gerald A Soff; Yimei Miao; Gemma Bendheim; Jeanette Batista; Jodi V Mones; Rekha Parameswaran; Cy R Wilkins; Sean M Devlin; Ghassan K Abou-Alfa; Andrea Cercek; Nancy E Kemeny; Debra M Sarasohn; Simon Mantha
Journal:  J Clin Oncol       Date:  2019-09-23       Impact factor: 44.544
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.